TG Therapeutics (NASDAQ:TGTX) Receives “Buy” Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of TG Therapeutics (NASDAQ:TGTX) in a research report report published on Thursday, Benzinga reports. HC Wainwright currently has a $45.00 target price on the biopharmaceutical company’s stock.

Several other equities research analysts have also commented on TGTX. The Goldman Sachs Group raised their price target on shares of TG Therapeutics from $12.00 to $13.00 and gave the company a neutral rating in a research note on Thursday, February 29th. B. Riley raised their price target on shares of TG Therapeutics from $24.00 to $29.00 and gave the company a buy rating in a research note on Monday, February 5th. Finally, StockNews.com lowered shares of TG Therapeutics from a buy rating to a hold rating in a research note on Saturday, February 24th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of Moderate Buy and a consensus target price of $29.00.

TG Therapeutics Stock Performance

Shares of NASDAQ TGTX opened at $13.99 on Thursday. The company has a quick ratio of 5.18, a current ratio of 5.92 and a debt-to-equity ratio of 0.62. The firm’s 50-day moving average price is $15.13 and its two-hundred day moving average price is $13.87. TG Therapeutics has a 52-week low of $6.46 and a 52-week high of $35.67. The stock has a market capitalization of $2.16 billion, a P/E ratio of 699.85 and a beta of 2.30.

TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earnings results on Wednesday, February 28th. The biopharmaceutical company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.12) by $0.03. TG Therapeutics had a net margin of 5.42% and a return on equity of 12.89%. The company had revenue of $43.97 million for the quarter, compared to analyst estimates of $40.06 million. During the same quarter last year, the business earned ($0.39) earnings per share. As a group, sell-side analysts forecast that TG Therapeutics will post -0.12 earnings per share for the current year.

Insider Activity at TG Therapeutics

In related news, Director Laurence N. Charney sold 22,000 shares of the firm’s stock in a transaction that occurred on Tuesday, March 12th. The shares were sold at an average price of $15.97, for a total transaction of $351,340.00. Following the transaction, the director now owns 215,229 shares in the company, valued at $3,437,207.13. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 9.20% of the company’s stock.

Institutional Trading of TG Therapeutics

Large investors have recently added to or reduced their stakes in the business. Pingora Partners LLC acquired a new position in TG Therapeutics in the 4th quarter worth approximately $27,000. PNC Financial Services Group Inc. boosted its stake in TG Therapeutics by 131.7% in the 3rd quarter. PNC Financial Services Group Inc. now owns 3,543 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 2,014 shares during the period. Macquarie Group Ltd. boosted its stake in TG Therapeutics by 102.3% in the 2nd quarter. Macquarie Group Ltd. now owns 10,190 shares of the biopharmaceutical company’s stock worth $43,000 after purchasing an additional 5,152 shares during the period. Coppell Advisory Solutions LLC acquired a new position in TG Therapeutics in the 2nd quarter worth approximately $46,000. Finally, KBC Group NV acquired a new position in TG Therapeutics in the 4th quarter worth approximately $54,000. 58.58% of the stock is currently owned by institutional investors.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.